Ensysce Biosciences Enrolls First Patient in Final Phase of PF614-MPAR-102 Clinical Study

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/9/2026

1. BRZE
2. TTAN
3. AAPL
4. CHYM
5. USO
6. QCOM
7. IRT
8. ASO
9. LAES
10. UNFI

Go back to Ensysce Biosciences Enrolls First Patient in Final Phase of PF614-MPAR-102 Clinical Study
(NASDAQ: ENSC) Delayed: 0.47 --0 (-0%)
Previous Close $0.47    52 Week High $ 
Open $0.48    52 Week Low $ 
Day High $0.50    P/E N/A 
Day Low $0.46    EPS $ 
Volume 587,146